Evidence map›Paper›PMID 41301153›Full record

ArticleBioengineering (Basel, Switzerland)2025

Marker-Less Lung Tumor Tracking from Real-Time Color X-Ray Fluoroscopic Images Using Cross-Patient Deep Learning Model.

Yongxuan Yan, Fumitake Fujii, Takehiro Shiinoki

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yongxuan YanGraduate School of Sciences and Technology for Innovation, Yamaguchi University, Ube 755-8611, Japan.ORCID 0000-0002-3069-2867
Fumitake FujiiGraduate School of Sciences and Technology for Innovation, Yamaguchi University, Ube 755-8611, Japan.ORCID 0000-0002-6496-5755
Takehiro ShiinokiGraduate School of Medicine, Yamaguchi University, Ube 755-8505, Japan.ORCID 0000-0002-0246-8489

Funding

Japan Science and Technology Agency JPMJSP2111
6 · The paper itself

Abstract

Fiducial marker implantation for tumor localization in radiotherapy is effective but invasive and carries complication risks. To address this, we propose a marker-less tumor tracking framework to explore the feasibility of a cross-patient deep learning model, aiming to eliminate the need for per-patient retraining. A novel degradation model generates realistic simulated data from digitally reconstructed radiographs (DRRs) to train a Restormer network, which transforms clinical fluoroscopic images into clean, DRR-like images. Subsequently, a DUCK-Net model, trained on DRRs, performs tumor segmentation. We conducted a feasibility study using a clinical dataset from 7 lung cancer patients, comprising 100 distinct treatment fields. The framework achieved an average processing time of 179.8 ms per image and demonstrated high accuracy: the median 3D Euclidean tumor center tracking error was 1.53 mm, with directional errors of 0.98±0.70 mm (LR), 1.09±0.74 mm (SI), and 1.34±0.94 mm (AP). These promising results validate our approach as a proof-of-concept for a cross-patient marker-less tumor tracking solution, though further large-scale validation is required to confirm broad clinical applicability.

Indexed as

deep learningfluoroscopic imageIGRTKV X-raytumor tracking

Identifiers

PMID41301153
PMCPMC12649688

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.